We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PApilloma TRIal against Cancer In young Adu…
We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PATRICIA (PApilloma TRIal against Cancer In…
Histologic chorioamnionitis (HCA) is implicated in the onset of preterm labor and delivery. Chorioamnionitis is a known risk factor for early-onset s…
Both bacteria and viruses play a role in the development of acute otitis media, however, the importance of specific viruses is unclear.
The authors previously reported an increased risk of hospitalisation for acute lower respiratory infection up to age 2 years in children delivered by…
Successful defence against viral pathogens requires the rapid recognition of virus-specific "danger signals" and the activation of both innate and ad…
The objective of this tudy was to assess the reactogenicity of two 2010 trivalent inactivated influenza vaccine (TIV) formulations among adults, incl…
In vitro investigations of human innate immune responses to extracellular bacteria commonly utilise killed preparations in preference to live...
In Australia the 7-valent pneumococcal conjugate vaccine (PCV7) is administered at 2, 4 and 6 months of age, with no booster dose.
Concerns about the risk of inducing immune deviation-associated "neonatal tolerance" as described in mice have restricted the widespread adoption...